0001299130-26-000081
SEC filingPost-restructuring Q1 showed marked profitability improvement with operating loss shrinking 98% to -$8.4M from sharply reduced expenses, while revenue held steady at $37.2M amid constrained instrument demand from U.S. funding challenges.
Revenue of $37.2M rose modestly 6.7% YoY, held back by constrained demand for instruments, particularly Vega, due to the U.S. funding environment contributing to elongated sales cycles and deferred orders. Management believes this dynamic persists, pressuring instrument placements despite pricing promotions. Consumables provided offset, supporting expectations for continued growth as Revio and Vega adoption expands ahead of the SPRQ-Nx commercial launch in May 2026.
Cash from operating activities used -$44.7M, comparable to -$44.1M YoY, as smaller net loss was tempered by working capital swings. Positive impacts came from decreased accounts receivable and increased other liabilities, partially offset by inventory buildup and accounts payable reductions—signaling preparation for platform ramps. Capital expenditures rose to $3.0M from $1.4M, focused on investing activities like manufacturing capacity, driving free cash flow to -$47.7M. Management notes investing centers on capex and investment portfolio management, with intent to hold unrealized loss positions to recovery.
The quarter embodies restructuring aftermath, with strategic refocus on accelerating HiFi sequencing adoption via Revio, Vega, and SPRQ-Nx kits. Ceasing high-throughput short-read development revises cash flow expectations from that segment, narrowing forward priorities. While profitability stabilized dramatically, instrument headwinds and cash burn highlight capital access importance; inability to raise funds when needed could adversely affect operations. Investors should monitor consumables traction and platform execution for sustained trajectory.